Company / Financials
Aligos Therapeutics, Inc. Financials
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.2M
FY2025 · -39.5% YoY
Net Income
-$24.2M
FY2025 · +81.6% YoY
Profit Margin
-1106.7%
FY2025 · net income / revenue
ROE
-45.2%
FY2025 · return on equity
Total Assets
$88.5M
FY2025
Total Debt
-
FY2025
Equity
$53.5M
FY2025
ROA
-27.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.2M-39.5% YoYNet Income HistoryProfit after all expenses and taxes-$24.2M+81.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$88.0M+1.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$20.7M-9.3% YoYR&D Expense HistoryResearch and development spending$69.5M-1.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.5MIncome Tax HistoryTotal income tax expense$314.0K-5.1% YoYEPS (Basic) HistoryBasic earnings per share-$20.94+38.8% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$20.94+38.8% YoYShares Outstanding HistoryWeighted average diluted shares outstanding79.9M+2559.9% YoY